Sectors
SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.
The Johnson & Johnson, GSK and AstraZeneca-backed drug developer raised the cash in a Patient Square Capital-led round that took its total funding beyond $200m.
GV has participated in a $41.9m series B extension for the birth control delivery service, which increased the round's size to $92.9m.
Bitwise Asset Management completed a $70m round backed by Coinbase at a $500m-plus valuation, while luxury goods wholesaler Joor raised $46m to take its overall funding to $81m.
Baidu contributed to a round pushing the medication supply platform developer's overall funding near to the $500m mark.
The Providence and Castlight Health-backed mental health services provider has closed its second funding round of the year, reportedly valuing it at $4.6bn.
Alexandria Venture Investments returned to invest in a series C round that lifted the radiopharmaceutical developer's overall funding to $258m.
Kraft Group has once again participated in a funding round for the RNA drug developer, having backed its series A round three years ago.
German Media Pool was among the participants in a $44.2m round that will fund the building of the cannabinoid product developer's production and research facility.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
